ESMO

After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
Fierce Pharma
Gilead Sciences
breast cancer
Trodelvy
ESMO
FDA
priority review
Flag link:
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Merck
Keytruda
cancer
oncology
ESMO
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
BioSpace
ESMO
Regeneron
Libtayo
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Merck
Keytruda
head and neck cancer
ESMO
Flag link:
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
BioSpace
ESMO
Bristol Myers Squibb
Nektar Therapeutics
Flag link:
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
Fierce Biotech
ESMO
Daiichi Sankyo
DS-7300
small cell lung cancer
Flag link:
Relay kicks off public offering, seeking $300M on heels of robust ESMO data
Relay kicks off public offering, seeking $300M on heels of robust ESMO data
Endpoints
ESMO
Relay Therapeutics
funding
Flag link:
ESMO 2022 – Springworks aims to Defi expectations
ESMO 2022 – Springworks aims to Defi expectations
EP Vantage
ESMO
desmoid tumors
GSK
Flag link:
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
Fierce Pharma
Amgen
lung cancer
ESMO
KRAS inhibitors
Flag link:
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
Fierce Biotech
ESMO
Pfizer
Ipsen
EZH2 inhibitors
Epizyme
Flag link:
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
Fierce Biotech
ESMO
Relay Therapeutics
RLY-4008
cholangiocarcinoma
Flag link:
ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first'
ESMO: GSK keeps the faith in anti-TIGIT plans; it's 'not always about being first'
Fierce Biotech
GSK
anti-TIGIT
ESMO
Flag link:
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Flag link:
Esmo 2022 – Galleri’s real-world exhibition disappoints
Esmo 2022 – Galleri’s real-world exhibition disappoints
EP Vantage
ESMO
Grail
Illumina
diagnostics
multi-cancer test
Galleri
Flag link:
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
Flag link:
SpringWorks, Eli Lilly and More Release Data Ahead of ESMO
SpringWorks, Eli Lilly and More Release Data Ahead of ESMO
BioSpace
SpringWorks Therapeutics
nirogacestat
desmoid tumors
Eli Lilly
ESMO
Flag link:
ESMO 2022 – the new liver cancer entrants line up
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
Flag link:
ESMO 2022 – Keytruda secures a renal cancer monopoly
ESMO 2022 – Keytruda secures a renal cancer monopoly
EP Vantage
Merck
Keytruda
renal cancer
Bristol Myers Squibb
Roche
ESMO
Flag link:

Pages